Clinical Trial Update: Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated subcutaneous fondaparinux 2.5 mg daily for the treatment of superficial thrombophlebitis; the trial has completed and results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Superficial Thrombophlebitis

Drugs mentioned

• Arixtra (fondaparinux) (fondaparinux)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Thrombosis, Venous | Phase 3 | Status: COMPLETED | Results posted: 2010-08-02